This page reflects content distributed at the time of publication. Company names and titles are shown as they were at that time. Minaris Regenerative Medicine has since been renamed Minaris Advanced Therapies.
This English translation is provided for reference purposes only. The original Japanese press release is the authoritative version.
Yokohama, Japan – June 14th, 2024
We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Myoridge Co., Ltd. have entered into a business alliance to support the development of manufacturing processes for regenerative medicine products through culture medium optimization.
In the development of manufacturing processes for regenerative medicine products, scaling up cell culture from laboratory scale to industrial scale is essential to efficiently produce cells that meet quality standards. However, during scale-up, challenges such as poor cell proliferation and failure to meet quality specifications often arise, creating a strong need for robust scale-up systems.
This alliance focuses on one of the most critical elements of cell culture—the culture medium. By leveraging approaches tailored to specific cells and processes, Myoridge and Minaris aim to create a new service for manufacturing process development for regenerative medicine products, centered on culture medium optimization.
Naohiro Makita, President & CEO, Myoridge commented:
“To contribute to the advancement of regenerative medicine, we have focused on optimizing culture media as the core of our business. Through this collaboration with Minaris, we are committed to applying our technology and expertise to the development of regenerative medicine products and paving the way for new therapeutic options.”
Hiroto Bando, President & CEO, Minaris Regenerative Medicine commented:
“Through our experience serving diverse clients, we have recognized the critical importance of culture medium optimization in regenerative medicine manufacturing. Myoridge’s technology and expertise in this area are exceptional, and we expect that the synergy between our companies will significantly improve manufacturing efficiency and robustness, accelerating timelines toward clinical trials.”
Moving forward, Myoridge and Minaris will continue to strengthen their collaboration, leveraging their respective strengths to create services that meet customer needs and contribute to the overall advancement of the regenerative medicine field.
About Myoridge Co., Ltd.
Myoridge is a Kyoto University–originated startup that has developed methods to alter cell phenotypes through culture media. With a proprietary database of culture medium components and advanced screening technology, Myoridge excels in high-throughput design of various media. The company offers its own culture medium products, innovative proposal-based optimization services, and contract development of model cells. Myoridge’s mission is to create value by solving cell culture challenges and contributing to the growth of the cell industry.
For more information, please visit: https://myoridge.co.jp/